Mode of action
The anti-diabetic effect of the biguanides appears to be distinct from their hypoglycaemic effect. In non-diabetic animals, the blood-sugar lowering dose of the biguanides is close to the lethal dose (Sterne, 1964) ; at clinically appropriate dose levels in man, blood sugar lowering is seen only in diabetic subjects. The anti-diabetic effect is unlikely to be due to increased insulin secretion for in obese and diabetic subjects, the administration of phenformin reduced the circulating insulin response to a glucose load (Grodsky et al., 1963; Abramson & Arky, 1967) . Furthermore, in human diabetics and in experimental animals, the administration of a biguanide reduces the quantity of insulin required to control hyperglycaemia (Sterne, 1964) . In some way, therefore, the biguanides appear to augment the hypoglycaemic effectiveness of circulating insulin, possibly by enhancing its stimulation of glucose utilization in muscle (Butterfield & Whichelow, 1962) . While this effect is most clearly apparent when the glucose/insulin interrelation is disturbed as in diabetes, it may, under special conditions, also be demonstrated in normals (Pereira, Wajchenberg & Schnaider, 1967) .
In adult diabetics, the biguanides may also effect a reduction in body weight, in serum triglycerides and in serum cholesterol (Schwartz, Mirsky & Schaefer, 1966) . Phenformin may owe these effects partly to its anorexigenic properties (Patel & Stowers, 1964) and partly to reduced circulating insulin in response to the lowered blood sugar, thus diminishing lipogenic and antilipolytic activity. Metformin has also been shown to have an antidiuretic effect in idiopathic diabetes insipidus (Katsuki & Ito, 1966 ).
Side-effects
The commonest side-effects of the biguanides are upon the gastro-intestinal tract, causing a metallic taste in the mouth, loss of appetite, nausea, diarrhoea and abdominal cramps. By starting with small doses and increasing the dose level slowly, the incidence of these side effects can be reduced (Pomeranze et al., 1959) ; in obese patients, particularly, a degree of anorexia may be a useful side-effect. Phenformin is available in timed-disintegration capsules, with which the incidence of gastro-intestinal side effects is said to be lower (Breidahl, 1961) (Sterne, 1964 (1959) claimed that there was improvement in overall control and a reduction in the frequency of hypoglycaemic attacks when phenformin was added to the regime. However, this improvement is usually attended by a reduction in the total insulin dosage which is itself likely to iron out the major swings from hypoglycaemia to reactionary hyperglycaemia and ketonaemia (Somogyi, 1959 (Fearnley & Chakrabarti, 1964; Fearnley et al., 1967; Fearnley, 1968) . Serum triglycerides and the pattern of circulating lipoproteins are also restored towards the normal by the biguanides (Schwartz, et al., 1966 DURING the past 20 years fibrinolysis, once an apparently rare and pathological phenomenon, has begun to emerge as the physiological antithesis of coagulation, a system whose function seems to be the removal of fibrin. Basically the system consists of plasminogen, an inactive enzyme precursor present in blood and other body fluids which can be converted to plasmin, an active proteolytic enzyme, by activators present in the blood, body fluids and the tissues. Antiplasmin is present in blood and neutralizes any plasmin liberated, so that in normal circumstance free plasmin is absent from circulating blood and the fibrinolytic system is in effect inert.
Since plasmin digests fibrinogen as well as fibrin, antiplasmin is a necessary safeguard against destruction of fibrinogen in fluid blood; but when fibrin is formed activator is adsorbed to it and converts the plasminogen incorporated with it to plasmin which in turn is adsorbed to fibrin 
